ADOPTED

NORTH CAROLINA GENERAL ASSEMBLY
AMENDMENT
Senate Bill 711

AMENDMENT NO. A1
(to be filled in by Principal Clerk)

S711-ABP-35 [v.14]

Amends Title [NO]
Fifth Edition

Date _____,2022

Senator Rabon

Moves to amend the bill on page 1, line 16, by rewriting the line to read:

"(2) As of February 2022, 37 states, four territories, and the District of Columbia have removed";

and on page 2, lines 27-28, by rewriting the lines to read:

"(6) Commission. – The Medical Cannabis Production Commission established in G.S. 90-113.118.";

and on page 6, lines 14-15, by rewriting the lines to read:

"(*l*) Advertising. – A physician is prohibited from advertising the physician's ability to issue written certifications.

(m) Prohibit Conflict. – A physician who provides written certifications to qualified patients may not be employed by or have any direct or indirect financial interest in a supplier or independent testing laboratory. A physician who provides written certifications to qualified patients may not directly or indirectly profit from a patient obtaining a written certification. This prohibition shall not prohibit a physician from charging an appropriate fee for patient visits.

(n) Rules. – The Commission may adopt rules regarding physicians to ensure the";

and on page 8, line 16, by rewriting the line to read:

"(h) Rules. – The Department shall adopt rules to";

and on page 10, line 11, by rewriting the line to read:

"no more than eight medical cannabis centers. Of the medical cannabis centers operated by each";

and on page 10, line 45, by rewriting the line to read:

"suppliers to produce cannabis and cannabis-infused products in licensed cannabis production"

and on page 12, lines 41- 42, by rewriting the lines to read:

"amount not less than ten thousand dollars ($10,000), plus five thousand dollars ($5,000) for each new production facility or medical cannabis center the supplier proposes to operate under the

ADOPTED

AMENDMENT NO. A1
(to be filled in by
Principal Clerk)

license, plus one thousand dollars ($1,000) for each existing production facility or medical cannabis center the supplier";

and on page 14, line 48, by rewriting the line to read:

"Article. A medical cannabis center shall not sell cannabis, cannabis-infused"

and on page 15, line 4, by rewriting the line to read:

"facilities approved under this Article. Except as provided in this section, the"

and on page 15, line 15, by rewriting the line to read:

"production facility operated by the supplier. Each supplier licensed under this Article shall report quarterly to the Commission on all cannabis or cannabis-infused products the supplier sold or manufactured in the previous quarter."

and on page 20, lines 1-2, by rewriting the lines to read:

"facility. An independent testing laboratory shall report the results of all required testing to the Department and to the Medical Cannabis Production Commission. The Commission shall have the authority to conduct its own testing of cannabis or cannabis-infused products in coordination with the Department.";

and on page 20, lines 18-19, by inserting the following between the lines:

"(d) No individual who owns, operates, has a direct or indirect financial interest in, or is employed by an independent testing laboratory shall own, operate, have a direct or indirect financial interest in, or be employed by a supplier, a production facility, or a medical cannabis center.";

and on page 21, lines 13-14, by rewriting the lines to read:

"(g) Advertisement of cannabis or cannabis-infused products in any manner except as allowed in this Article is prohibited.

(h) The Department, in consultation with the Commission, shall adopt rules to define and monitor standards for a medical cannabis center's name, signage, and logo to ensure a medical rather than recreational disposition.";

and on page 22, lines 29-41, by rewriting the lines to read:

"(a) It is the intent of the General Assembly that the North Carolina Collaboratory undertake objective, scientific research regarding the administration of cannabis or cannabis-infused products as part of medical treatment. The Collaboratory shall create a program to be known as the North Carolina Cannabis Research Program.

(b) The research conducted under this section may involve the development of quality control, purity, and labeling standards for cannabis dispensed through the regulated medical cannabis supply system; sound advice and recommendations on the best practices for the safe and efficient cultivation of cannabis; and analysis of genetic and healing properties of the many

ADOPTED

AMENDMENT NO. A1
(to be filled in by
Principal Clerk)

S711-ABP-35 [v.14]

varied strains of cannabis to determine which strains may be best suited for a particular condition or treatment.

(c) Notwithstanding any other provision of State law, and subject to the requirements of the Commission, the Collaboratory and its academic research partners may possess, transport, store, test, and dispose of cannabis as necessary to conduct scientific research pursuant to this section.";

and on page 22, line 42, to page 23, line 6, by deleting the lines;

and on page 24, line 41, to page 25, line 4, by rewriting the lines to read:

"**SECTION 2.(a)** The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a. and (a)(1)c. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)d., and (a)(1)e., the initial term shall be three years; for each member appointed pursuant to G.S. 90-113.113(a)(1)f. and (a)(1)g. the initial term shall be two years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b).";

and on page 25, lines 17-18, by rewriting the lines:

"**SECTION 2.(c)** Within 270 days of the effective date of this act, the Department of Health and Human Services must adopt rules as required by G.S. 90-113.115(h).";

and on page 26, line 33-34, by rewriting the line to read:

"**SECTION 4.5.(b)** This section becomes effective December 1, 2022, and applies to motions filed on or after that date.".

SIGNED _____
Amendment Sponsor

SIGNED _____
Committee Chair if Senate Committee Amendment

The official copy of this document, with signatures and vote information, is available in the Senate Principal Clerk's Office